WO2001037829A1 - Composición que comprende aceites ozonizados y/o otros productos naturales y/o sintéticos ozonizados, y su empleo en composiciones farmacéuticas, cosméticas, dietéticas o de suplementos alimentarios, en los campos humano y veterinario - Google Patents
Composición que comprende aceites ozonizados y/o otros productos naturales y/o sintéticos ozonizados, y su empleo en composiciones farmacéuticas, cosméticas, dietéticas o de suplementos alimentarios, en los campos humano y veterinario Download PDFInfo
- Publication number
- WO2001037829A1 WO2001037829A1 PCT/ES2000/000208 ES0000208W WO0137829A1 WO 2001037829 A1 WO2001037829 A1 WO 2001037829A1 ES 0000208 W ES0000208 W ES 0000208W WO 0137829 A1 WO0137829 A1 WO 0137829A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- weight
- concentration
- total
- respect
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 239000000047 product Substances 0.000 title claims abstract description 32
- 239000003921 oil Substances 0.000 title claims abstract description 15
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 14
- 239000002537 cosmetic Substances 0.000 title claims abstract description 13
- 230000000378 dietary effect Effects 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 title claims description 3
- 235000005911 diet Nutrition 0.000 title abstract description 7
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 22
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 22
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims abstract description 21
- 239000013543 active substance Substances 0.000 claims abstract description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 239000000654 additive Substances 0.000 claims abstract description 6
- 239000003981 vehicle Substances 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 21
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 108010024636 Glutathione Proteins 0.000 claims description 6
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 229960003180 glutathione Drugs 0.000 claims description 6
- 235000003969 glutathione Nutrition 0.000 claims description 6
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 6
- 229960003987 melatonin Drugs 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 5
- 230000035882 stress Effects 0.000 claims description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 235000007882 dietary composition Nutrition 0.000 claims description 4
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 claims description 4
- 235000020778 linoleic acid Nutrition 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- 150000003254 radicals Chemical class 0.000 claims description 4
- 231100000397 ulcer Toxicity 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 230000036542 oxidative stress Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 230000004075 alteration Effects 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims description 2
- 229940093797 bioflavonoids Drugs 0.000 claims description 2
- 229960004203 carnitine Drugs 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000037149 energy metabolism Effects 0.000 claims description 2
- 235000004626 essential fatty acids Nutrition 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
- 229960002715 nicotine Drugs 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 239000003075 phytoestrogen Substances 0.000 claims description 2
- 239000006041 probiotic Substances 0.000 claims description 2
- 230000000529 probiotic effect Effects 0.000 claims description 2
- 235000018291 probiotics Nutrition 0.000 claims description 2
- 150000003648 triterpenes Chemical class 0.000 claims description 2
- GQDDNDAYOVNZPG-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C[C]2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3N=C21 GQDDNDAYOVNZPG-SCYLSFHTSA-N 0.000 claims description 2
- 229960000317 yohimbine Drugs 0.000 claims description 2
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N fumaric acid group Chemical group C(\C=C\C(=O)O)(=O)O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- 235000016709 nutrition Nutrition 0.000 claims 2
- 230000035764 nutrition Effects 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 12
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 235000013618 yogurt Nutrition 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000004006 olive oil Substances 0.000 description 5
- 235000008390 olive oil Nutrition 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000019486 Sunflower oil Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 239000002600 sunflower oil Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010039509 Scab Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229940119170 jojoba wax Drugs 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- RJFAYQIBOAGBLC-UHFFFAOYSA-N 2-amino-4-methylselanyl-butanoic acid Chemical compound C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 2
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 2
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 2
- 108010063907 Glutathione Reductase Proteins 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000003851 biochemical process Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 239000008278 cosmetic cream Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- -1 for example Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 238000006385 ozonation reaction Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000035806 respiratory chain Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- HXBYBCASAVUYKF-GVYWOMJSSA-N (4r,5s,6r,7r)-4,5,6,7,8-pentahydroxyoctane-2,3-dione Chemical compound CC(=O)C(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO HXBYBCASAVUYKF-GVYWOMJSSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OPJWPPVYCOPDCM-UHFFFAOYSA-N 2-ethylhexyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC OPJWPPVYCOPDCM-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000001907 Mushroom Poisoning Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- IZFHEQBZOYJLPK-UHFFFAOYSA-N dihydrolipoic acid Chemical compound OC(=O)CCCCC(S)CCS IZFHEQBZOYJLPK-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-N disodium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound [Na+].[Na+].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O ZGTMUACCHSMWAC-UHFFFAOYSA-N 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- WURFKUQACINBSI-UHFFFAOYSA-M ozonide Chemical compound [O]O[O-] WURFKUQACINBSI-UHFFFAOYSA-M 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 235000021101 unsweetened yogurt Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
- A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
- A23C9/1422—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of milk, e.g. for separating protein and lactose; Treatment of the UF permeate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2210/00—Physical treatment of dairy products
- A23C2210/20—Treatment using membranes, including sterile filtration
- A23C2210/208—Removal of bacteria by membrane filtration; Sterile filtration of milk products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- the present invention relates to compositions comprising ozonized oils and / or ozonized natural and / or synthetic products, and thioctic acid and / or its derivatives, together with, optionally, other additional components.
- Said compositions are suitable for the preparation of pharmaceutical, cosmetic, dietary and food supplement compositions in humans and animals.
- Ozonized oils and ozonized natural or synthetic products are natural or synthetic products that contain molecules with carbon-carbon (olefinic) double bonds, which, when subjected to reaction with ozone, conveniently produce a mixture of ozonides, oligomeric ozonides and various products rich in active oxygen, peroxidic, hydroperoxidic, etc.
- These substances are carriers of active oxygen and have a marked germicidal character, they also have the capacity to stimulate various oxidation-reduction enzymatic processes in cells, such as glutathione peroxidase, glutathione reductase, glucose-6- phosphate dehydrogenase, superoxide dismutase, catalase, etc.
- Thioctic acid also known as alpha lipoic acid, alpha-lipoate, 1,2-dithiolan-3-pentanoic acid, etc. It has properties as a metabolic antioxidant, since many enzyme systems in animal cells treat it as a substrate for bioreductions. Supplemented thioctic acid is reduced to dihydrolipoate at the expense of reduction cell equivalents, such as NADH and NADPH. As the consumption of these reduction equivalents increases, the rate of cellular metabolism also increases to meet the increased demand. Thus, a property of thioctic acid is to facilitate the use of the cell's own metabolic capacities for recycling and potentiation. It is also considered to be capable of regenerating other natural antioxidants, such as vitamins C and E, glutathione, etc.
- Thioctic acid has been used in Europe for years as a non-toxic nutrient, for its ability to help maintain or restore liver health, as a treatment for various toxin-related diseases (mushroom poisoning, radiation, etc.) and in alcoholic hepatitis . Its usefulness has also been reported in AIDS patients receiving antiviral or antibiotic treatments, to contribute to the normalization of liver enzymes.
- compositions hereinafter, a composition of the invention, comprising (i) one or more ozonized oils and / or one or more ozonized natural and / or synthetic products, and (ii) thioctic acid and / or its derivatives, in which each of the components is in a concentration between 0.01% and 99.99% by weight with respect to the total, preferably between 0.01% and 50% by weight.
- Ozonized oils and natural or synthetic products can be obtained by the procedures described in the prior art [Gabelein, K., "Therapeutician eigenschaften der aus ozongas ge finely divided ge finely divided ge finely divided organische ozonide", Erfahr. hk 23, 167-173 (1974); Gabelein, K., “Eine ganzThat qualitat der ⁇ zontagen”, Erfahr. hk 26, 203-209 (1977); German patent DE 12 55 660 (Gabelein, K., 1968); Japanese patent JP 55017351 (Rikagaku, K., 1980)].
- the term "derivative” means substances constituted by the original molecule (that is, from which they are derived), in which some of its constituent parts (chemical functional groups or atoms) may have been replaced by some other chemical functional group, atom or molecule, in which the main structure is that of the original molecule. This term also includes the possibility that the chemical addition of some other chemical functional group, atom or molecule, to one of the links of the original structure has been made.
- conjugate means substances constituted by the original molecule, or essential part thereof, chemically combined with another of approximately equal size, or larger, generally of the type of bases, such as those they constitute the DNA, or others related or derived from them.
- conjugate refers to any more complex form that contains melatonin or its derivatives and that serves to transport them to specific structures of certain cells.
- composition of the invention may contain, if desired, in varying amounts, one or more substances. active and / or additives and / or vehicles and / or excipients suitable for pharmaceutical, cosmetic, dietary use, or as a food supplement, in the human and veterinary fields.
- the composition of the invention contains one or more active substances that significantly enhance its effectiveness, selected from, for example, substances that facilitate the stimulation of cellular biochemical processes, such as oxide-reduction of oxidizing metabolites and / or reducing agents, glycolysis, oxidative decarboxylation of pyruvic acid, the Krebs cycle, the cellular respiratory chain, etc., as well as substances that facilitate the synthesis at the cellular level of glutathione, NAD-NADH, NADP-NADPH, flavonoids, enzymes, cofactors, etc.
- active substances that significantly enhance its effectiveness selected from, for example, substances that facilitate the stimulation of cellular biochemical processes, such as oxide-reduction of oxidizing metabolites and / or reducing agents, glycolysis, oxidative decarboxylation of pyruvic acid, the Krebs cycle, the cellular respiratory chain, etc., as well as substances that facilitate the synthesis at the cellular level of glutathione, NAD-NADH, NADP-NADPH, flavonoids, enzymes, cofactor
- active substances are, by way of illustration not limiting the scope of the present invention, among others: - amino acids and their derivatives, for example, cysteine, arginine, glycine, N-acetyl-cysteine, etc., and derivatives thereof. same, in a concentration, if present, between 0.01% and 25% by weight with respect to the total; - organic acids and their derivatives, for example, fumaric, succinic, eicosapentanoic, hyaluronic, pantothenic acid, etc. , and derivatives thereof, in a concentration, if present, between 0.01% and 25% by weight with respect to the total;
- - essential microelements or trace elements for example, selenium, magnesium, manganese, zinc, copper, silver, etc., in any form (salts, oxides, hydroxides, etc.), in a concentration, if they are present, between 0.01% and 10% by weight with respect to the total; vitamins, their precursors and derivatives, for example, vitamins of groups A, B, C, D, E and F, their precursors and derivatives, in a concentration, if present, between 0.01% and 25% by weight with respect to the total;
- alkaloids such as nicotine, yohimbine, carnitine, galantoin, etc., their derivatives and precursors, in a concentration, if present, between 0.01% and 10% by weight with respect to the total;
- - film-forming compounds such as skin-forming film-forming compounds, for example, polyfluorocarbons, such as FOMBLIN (a polyfluoro-carbon that forms a protective film on the skin and allows the exchange of oxygen) and the like, in a concentration, if present, between 0.01% and 10% by weight with respect to the total;
- FOMBLIN a polyfluoro-carbon that forms a protective film on the skin and allows the exchange of oxygen
- composition of the invention may contain one or more of the active substances mentioned above.
- composition of the invention is characterized by the association between (i) ozonized oils and / or other natural and / or synthetic ozonized products, and (ii) thioctic acid and / or its derivatives, optionally together with one or more of the substances of the types mentioned above and because said association has a potentiating effect on the activities of said ozonized oils and ozonized natural or synthetic products, which is especially advantageous in cosmetic, dietary, food supplement, and pharmaceutical uses, for example, in the prevention and treatment of dermatitis, infections, ulcers (including gastroduodenal ulcers), bedsores, burns and other tissue lesions, including the gastrointestinal tract, various cell dysfunctions, alterations of energy metabolism and oxidative protective enzyme systems , aging, effects derived from free radicals, condi tions related to oxidative stress and stress in general, and others.
- association of compounds provided by this invention also acts in the metabolism of carbohydrates, fatty acids, lipids, in the cellular respiratory chain, etc. , activating to a greater extent the mitochondrial functionality, as well as others.
- compositions of the invention are useful for the preparation of medicaments, cosmetics, dietary compositions, food supplements, etc. for human and / or veterinary use.
- the invention also provides a pharmaceutical composition comprising a composition of the invention and one or more pharmaceutically acceptable excipients and / or carriers.
- the invention provides a pharmaceutical composition suitable for the prevention and treatment of stress-related cellular dysfunctions. oxidative and with the malfunction of cellular biochemical processes in general.
- the dietary compositions and nutritional supplements provided by this invention comprise a composition of the invention together with one or more additives and / or acceptable carriers, matrices or carriers.
- the final product obtained contains part of the unreacted starting olive oil, and a mixture of monomeric and oligomeric ozonides, peroxides, hydroperoxides, etc., all of them rich in active oxygen.
- Capsules with the following composition are prepared:
- the efficacy of the encapsulated product was evaluated in 10 patients aged between 29 and 61 years, who were carriers of gastroduodenal ulcers between 0.5 and 2 cm in diameter, whose gastric cultures had been positive for the presence of Helicobacter pylori.
- the indicated treatment consisted of taking one capsule of the product when getting up, on an empty stomach, and another at bedtime, after more than 2 hours of the last meal of the day, during the first 7 days, and taking 1 capsule of the product at bedtime, after more than 2 hours of the last meal of the day, for 35 days.
- a post-resurfacing epithelial repair cream is prepared with the following composition:
- the product is prepared as a cosmetic cream, mixing the components in a turboemulsifier.
- the various components (from 4 to 22) are mixed with the usual procedure.
- the ozonated L15 jojoba oil is heated to about 40 ° C, in a hot water bath, and thioctic acid and glutathione are dissolved therein, then cooling.
- This mixture is added to the rest of the components in the turboemulsifier following the different "oil" phases. Once the emulsion is formed, it cools rapidly. Once cooled, the cream is packaged in 50 ml plastic tubes.
- Efficacy test The efficacy of the product was evaluated in 10 subjects aged between 43 and 64 years, who underwent laser facial resurfacing treatment.
- the cream was applied immediately after treatment, and, twice a day, during the following days.
- the effects after resurfacing treatments are usually stinging, scabbing, redness and inflammation.
- moisturizing cosmetic creams with antioxidant components are used, but, frequently, these sequels last for 7 or 8 days, and, in some cases, are complicated by over-added infections.
- Yogurts enriched with ozonated vegetable oil and thioctic acid were prepared, suitable for the regulation of slow and incomplete digestions and intestinal disorders, which presented the following composition:
- Efficacy test The efficacy of the product was evaluated in a group of subjects who frequently suffered from slow and heavy digestion, as well as frequent gastrointestinal disorders, accompanied by diarrhea episodes.
- Capsules with the following composition are prepared:
- 150 g of ozonized oil are heated to 402C, in a hot water bath, and mixed in the same order, 4 g of thioctic acid and 1 g of selenium methionine.
- the mixture is then cooled to room temperature and 30 g of LC1 lactobacilli are added, mixing until a homogeneous dispersion is obtained.
- 800 g of micronized clay is introduced into a high-speed mixer, covered and stirring is begun, and the previous mixture is added little by little, through a side hole, until absorption is obtained. Total of it.
- the product is encapsulated in gastric capsules (of gelatin) of 1 g of product.
- the following treatment was indicated: Perform 6 hours of moderate physical exercise per week (fitness), observe a maintenance diet of 3 kcal, take one capsule of the product when getting up, fasting, and another at bedtime, after more than 2 hours of the last food of the day, during the first 10 days, and take 1 capsule of the product at bedtime, after more than 2 hours of the last food of the day, for another 32 days.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Animal Husbandry (AREA)
- Water Supply & Treatment (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU50796/00A AU5079600A (en) | 1999-11-25 | 2000-06-09 | Composition comprising ozonized oils and/or other ozonized natural and/or synthetic products and their use in pharmaceutical, cosmetic, dietetic or food supplement compositions in human and veterinary medicine |
DE60040096T DE60040096D1 (de) | 1999-11-25 | 2000-06-09 | Zusammensetzung enthaltend ozonisierte öle und/oder andere natürliche und/oder synthetische ozonizierte produkte und ihre verwendung in pharmazeutischen, kosmetischen, diätetischen oder nahrungsergänzenden zusammensetzungen in human- und veterinärgebieten |
EP00935232A EP1273295B1 (en) | 1999-11-25 | 2000-06-09 | Composition comprising ozonized oils and/or other natural and/or synthetic ozonized products and use thereof in pharmaceutical, cosmetic, dietetic or food supplement compositions, in the human and veterinary fields |
US10/155,472 US20030049333A1 (en) | 1999-11-25 | 2002-05-24 | Composition that comprises ozonised oils and/or other natural and/or synthetic ozonised products, and use thereof in pharmaceutical, cosmetic, dietary or food supplement products, in the human and veterinary fields |
US10/969,136 US20050113441A1 (en) | 1999-11-25 | 2004-10-19 | Composition that comprises ozonised oils and/or other natural and/or synthetic ozonised products, and use thereof in pharmaceutical, cosmetic, dietary or food supplement products, in the human and veterinary fields |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009902602A ES2162586B1 (es) | 1999-11-25 | 1999-11-25 | Composicion que comprende aceites ozonizados y/o otros productos naturales y/o sinteticos ozonizados, y su empleo en composiciones farmaceuticas, cosmeticas, dieteticas o de suplementos alimentarios, en los campos humano y veterinario |
ESP9902602 | 1999-11-25 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/155,472 Continuation-In-Part US20030049333A1 (en) | 1999-11-25 | 2002-05-24 | Composition that comprises ozonised oils and/or other natural and/or synthetic ozonised products, and use thereof in pharmaceutical, cosmetic, dietary or food supplement products, in the human and veterinary fields |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001037829A1 true WO2001037829A1 (es) | 2001-05-31 |
Family
ID=8310725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2000/000208 WO2001037829A1 (es) | 1999-11-25 | 2000-06-09 | Composición que comprende aceites ozonizados y/o otros productos naturales y/o sintéticos ozonizados, y su empleo en composiciones farmacéuticas, cosméticas, dietéticas o de suplementos alimentarios, en los campos humano y veterinario |
Country Status (7)
Country | Link |
---|---|
US (2) | US20030049333A1 (es) |
EP (1) | EP1273295B1 (es) |
AT (1) | ATE406154T1 (es) |
AU (1) | AU5079600A (es) |
DE (1) | DE60040096D1 (es) |
ES (1) | ES2162586B1 (es) |
WO (1) | WO2001037829A1 (es) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1325734A1 (de) * | 2001-11-22 | 2003-07-09 | Pharmoxid Arznei GmbH & Co. KG | Verfahren zur Herstellung von Ozoniden und Peroxiden von Fettsäuren oder deren Ester in Form einer streichfähigen Salbe |
WO2003085072A1 (es) * | 2002-04-08 | 2003-10-16 | Centro Nacional De Investigaciones Cientificas (Cnic) | Procedimiento para la obtencion de aceites y grasas vegetales ozonizados y aplicacion de estos productos con fines farmaceuticos y cosmetologicos |
WO2012168770A1 (en) | 2011-06-10 | 2012-12-13 | Universita' Del Salento | Process for ozonization of a vegetable oil |
ES2646335A1 (es) * | 2016-06-10 | 2017-12-13 | Nicolás RUBIO GARCÍA | Aceite ozonizado con antioxidantes |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6365623B1 (en) * | 1997-11-17 | 2002-04-02 | Nicholas V. Perricone | Treatment of acne using lipoic acid |
ECSP034481A (es) * | 2003-02-14 | 2004-09-28 | Jacome Neptali Rene Cristobal Ordonez | Proceso de produccion de crema estable de ozono a partir de aceites vegetales insaturados y equipo utilizado |
PT1754478E (pt) | 2005-08-04 | 2009-03-31 | Encrypta Gmbh | Composição líquida compreendendo arginina e ácido alfalipóico e sua utilização para melhorar a função sexual |
ITRM20050514A1 (it) * | 2005-10-17 | 2007-04-18 | Gabriele Maietta | Olio ozonizzato, principio attivo di elevata stabilita' a base di perossidi utilizzabile per applicazioni terapeutiche mediche e per trattamenti domiciliari similari a quelli dell'ozonoterapia, senza l'utilizzo di ozono gassoso. |
GB0521873D0 (en) * | 2005-10-27 | 2005-12-07 | Karim Steven | Pure 03 serums |
EP1938792A1 (en) * | 2006-12-29 | 2008-07-02 | Vanity Line S.p.A. | Cosmetic complex compound |
WO2010128906A1 (en) * | 2009-05-06 | 2010-11-11 | Sca Hygiene Products Ab | Sanitary article with probiotic effect |
ITFI20090118A1 (it) * | 2009-05-27 | 2010-11-27 | Italmed S R L | Miscele composte di origine vegetale ad attivita' antisettica. |
WO2011129784A2 (en) * | 2010-04-15 | 2011-10-20 | Mert-Koz Kozmetik Kimya Gida Ambalaj Sanayi Ve Dis Ticaret Limited Sirketi | Water-based personal care and cleaning liquid comprising ozone derivative of vegetable oils and its method of obtaining |
ITMI20110354A1 (it) | 2011-03-07 | 2012-09-08 | Neovalis S R L | Composizione a base di olio ozonizzato per uso topico |
JP6153241B2 (ja) * | 2011-08-18 | 2017-06-28 | 国立大学法人佐賀大学 | 肝機能障害予防改善剤 |
ITBA20120052A1 (it) * | 2012-09-06 | 2014-03-07 | Guerra Lorenzo | "dispositivo per la gassificazione di una matrice lipidica in ambiente a temperatura controllata" |
KR101618054B1 (ko) | 2014-03-20 | 2016-05-09 | 동명대학교산학협력단 | 오존연고와 베타글루칸 및 히아루론산을 이용한 화장품 제조방법 |
ITUB20155250A1 (it) * | 2015-11-24 | 2017-05-24 | Apuzzo Dario | Nuova composizione nutraceutica, somministrabile per via orale, utile per esercitare una potente stimolazione del metabolismo, in particolare del metabolismo energetico muscolare. |
IT201700063112A1 (it) * | 2017-06-08 | 2018-12-08 | Project & Communications Ltd | Formulazione per uso orale comprendente olio ozonizzato nella prevenzione e/o trattamento di lesioni cutanee causate dall’esposizione a radiazioni ionizzanti e/o trattamento chemioterapico. |
IT201800002990A1 (it) * | 2018-02-23 | 2019-08-23 | Biomedical Res Srl | Composizione a base di una miscela di fattori biologici isolata dal colostro e oli vegetali ozonizzati per l’uso nel trattamento di vaginiti e vaginosi |
TR201804452A2 (tr) * | 2018-03-29 | 2018-06-21 | Ahmet Uemit Sabanci | Ozonlanmiş yağ i̇çeren solüsyonlar |
CN114096649A (zh) * | 2019-07-16 | 2022-02-25 | 日清奥利友集团株式会社 | 用于制造精制食用油和/或脂肪的方法,用于改善食用油和/或脂肪的光暴露气味的方法,以及精制食用油和/或脂肪 |
EP3949980A1 (en) | 2020-08-04 | 2022-02-09 | Vassiliki Griva | Compositions for the treatment of atopic dermatitis containing ozonated oils and natural antioxidant agents |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1255660B (de) * | 1964-06-08 | 1967-12-07 | Dr Klaus Gaebelein | Verfahren zur Herstellung von Glykolaethergruppen enthaltenden Acetalperoxiden |
EP0076647A2 (en) * | 1981-10-02 | 1983-04-13 | HANA Biologics Incorporated | Culture media for cells originating from the immune system |
US4451480A (en) * | 1982-04-16 | 1984-05-29 | James Howard Brown | Method of treating acne using ozonized materials |
EP0235528A1 (de) * | 1986-03-01 | 1987-09-09 | Dr. J. Hänsler GmbH | Verfahren zur Herstellung von stabilen ozonisierten Ölen aus ungesättigten Pflanzenölen |
RU2008898C1 (ru) * | 1992-08-26 | 1994-03-15 | Геннадий Иванович Суколин | Способ лечения грибковых и вирусных заболеваний кожи и/или ногтевых пластинок |
FR2730636A1 (fr) * | 1995-02-16 | 1996-08-23 | Cosmart Ag | Huile vegetale naturelle enrichie en ozonides, compositions cosmetiques ou pharmaceutiques la contenant et utilisations |
US5904924A (en) * | 1997-11-04 | 1999-05-18 | Oncologics, Inc. | Green nutritional powder composition |
US5948443A (en) * | 1996-02-23 | 1999-09-07 | Medical Doctor's Research Institute, Inc. | Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
US5977162A (en) * | 1996-09-16 | 1999-11-02 | Seidman; Michael D. | Therapeutic treatment for auditory function |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US451480A (en) * | 1891-05-05 | Half to william | ||
US4591602A (en) * | 1982-04-16 | 1986-05-27 | James H. Brown | Ozonide esters and topical compositions containing same |
US5364879A (en) * | 1988-06-24 | 1994-11-15 | Cliveden Ltd. | Medical uses of trioxolane and diperoxide compounds |
US5709868A (en) * | 1995-09-20 | 1998-01-20 | Perricone; Nicholas V. | Lipoic acid in topical compositions |
WO2000024734A1 (en) * | 1998-10-26 | 2000-05-04 | The Research Foundation Of State University Of New York | Lipoic acid derivatives and their use in treatment of disease |
US6080401A (en) * | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
US6284786B1 (en) * | 1999-02-16 | 2001-09-04 | The Center For The Improvement Of Human Functioning, Int'l., Inc. | Treatment of cancer using lipoic acid in combination with ascorbic acid |
-
1999
- 1999-11-25 ES ES009902602A patent/ES2162586B1/es not_active Expired - Fee Related
-
2000
- 2000-06-09 DE DE60040096T patent/DE60040096D1/de not_active Expired - Fee Related
- 2000-06-09 AU AU50796/00A patent/AU5079600A/en not_active Abandoned
- 2000-06-09 WO PCT/ES2000/000208 patent/WO2001037829A1/es active IP Right Grant
- 2000-06-09 EP EP00935232A patent/EP1273295B1/en not_active Expired - Lifetime
- 2000-06-09 AT AT00935232T patent/ATE406154T1/de not_active IP Right Cessation
-
2002
- 2002-05-24 US US10/155,472 patent/US20030049333A1/en not_active Abandoned
-
2004
- 2004-10-19 US US10/969,136 patent/US20050113441A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1255660B (de) * | 1964-06-08 | 1967-12-07 | Dr Klaus Gaebelein | Verfahren zur Herstellung von Glykolaethergruppen enthaltenden Acetalperoxiden |
EP0076647A2 (en) * | 1981-10-02 | 1983-04-13 | HANA Biologics Incorporated | Culture media for cells originating from the immune system |
US4451480A (en) * | 1982-04-16 | 1984-05-29 | James Howard Brown | Method of treating acne using ozonized materials |
EP0235528A1 (de) * | 1986-03-01 | 1987-09-09 | Dr. J. Hänsler GmbH | Verfahren zur Herstellung von stabilen ozonisierten Ölen aus ungesättigten Pflanzenölen |
RU2008898C1 (ru) * | 1992-08-26 | 1994-03-15 | Геннадий Иванович Суколин | Способ лечения грибковых и вирусных заболеваний кожи и/или ногтевых пластинок |
FR2730636A1 (fr) * | 1995-02-16 | 1996-08-23 | Cosmart Ag | Huile vegetale naturelle enrichie en ozonides, compositions cosmetiques ou pharmaceutiques la contenant et utilisations |
US5948443A (en) * | 1996-02-23 | 1999-09-07 | Medical Doctor's Research Institute, Inc. | Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
US5977162A (en) * | 1996-09-16 | 1999-11-02 | Seidman; Michael D. | Therapeutic treatment for auditory function |
US5904924A (en) * | 1997-11-04 | 1999-05-18 | Oncologics, Inc. | Green nutritional powder composition |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 199435, Derwent World Patents Index; AN 1994-284073D, XP002941525 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1325734A1 (de) * | 2001-11-22 | 2003-07-09 | Pharmoxid Arznei GmbH & Co. KG | Verfahren zur Herstellung von Ozoniden und Peroxiden von Fettsäuren oder deren Ester in Form einer streichfähigen Salbe |
WO2003085072A1 (es) * | 2002-04-08 | 2003-10-16 | Centro Nacional De Investigaciones Cientificas (Cnic) | Procedimiento para la obtencion de aceites y grasas vegetales ozonizados y aplicacion de estos productos con fines farmaceuticos y cosmetologicos |
WO2012168770A1 (en) | 2011-06-10 | 2012-12-13 | Universita' Del Salento | Process for ozonization of a vegetable oil |
ES2646335A1 (es) * | 2016-06-10 | 2017-12-13 | Nicolás RUBIO GARCÍA | Aceite ozonizado con antioxidantes |
Also Published As
Publication number | Publication date |
---|---|
US20050113441A1 (en) | 2005-05-26 |
DE60040096D1 (de) | 2008-10-09 |
AU5079600A (en) | 2001-06-04 |
US20030049333A1 (en) | 2003-03-13 |
ES2162586B1 (es) | 2002-07-01 |
ES2162586A1 (es) | 2001-12-16 |
EP1273295B1 (en) | 2008-08-27 |
ATE406154T1 (de) | 2008-09-15 |
EP1273295A1 (en) | 2003-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001037829A1 (es) | Composición que comprende aceites ozonizados y/o otros productos naturales y/o sintéticos ozonizados, y su empleo en composiciones farmacéuticas, cosméticas, dietéticas o de suplementos alimentarios, en los campos humano y veterinario | |
JP5517124B2 (ja) | 炎症性障害および/または関節障害の治療、共治療または予防のための三環式ジテルペンおよびそれらの誘導体の使用 | |
EP2127646B1 (en) | Agent for relief or prevention of xerostomia | |
ES2260293T3 (es) | Composicion que comprende acido hidroxicitrico y garcinol para reduccion de peso. | |
US8124139B2 (en) | Compound preparation for quickly reducing oxidative stress and preparation of the same | |
US20110287061A1 (en) | Dietary composition and method for promoting healthy hair growth and melanogenesis | |
KR101517095B1 (ko) | 천연 추출물을 이용한 치주질환 치료 및 예방용 조성물 | |
US20040214750A1 (en) | Medicaments for healing skin conditions in humans | |
JP2010030901A (ja) | ストレス症状の緩和または予防剤 | |
BRPI0610415A2 (pt) | utilização de glicerìdeo(s) de cadeia média, composição para a absorção oral e destinada a prevenir e/ou tratar a matérias queratìnicas secas e/ou sensibilizadas e processo de tratamento não terapêutico para prevenir e/ou tratar as matérias queratìnicas secas e/ou fragilizadas | |
CN105920202A (zh) | 一组护齿益智除臭的辅酶q10口香糖 | |
WO2015015816A1 (ja) | 繊維芽細胞賦活剤 | |
CN105555289B (zh) | 可可多酚及其在治疗或预防嗜酸性食管炎中的效用 | |
US20080089905A1 (en) | COMPOUNDS FOR STIMULATING STEM CELL PROLIFERATION INCLUDING AFA-OMEGA (EtOH) | |
KR100515923B1 (ko) | 바이오 복합 단백질 조성방법 | |
AU2021104246A4 (en) | Slimming probiotic soft capsule and preparation method thereof | |
RU2765266C1 (ru) | Состав для производства натуральной леденцовой карамели | |
JP2003055245A5 (es) | ||
CA2438164A1 (en) | Use of preparations containing selenite or selenate | |
CN107801830A (zh) | 不含胶基可食用的牙齿口腔清洁片 | |
Singh et al. | Role of Nutraceuticals in Maintaining Oral and Periodontal Health | |
CN116584661A (zh) | 用于身体机能修复的小分子复合肽配方及用途、食用方法 | |
WO2024028659A1 (en) | Combination of palmitoylethanolamide and equisetum and food, nutraceutical and/or pharmaceutical compositions containing it for use in neuronal protection and regeneration | |
BG3812U1 (bg) | Хранителна добавка | |
US20210290711A1 (en) | Hempseed oil compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10155472 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000935232 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2000935232 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000935232 Country of ref document: EP |